Indivior PLC Updates on AEF0117 Development

Ticker: INDV · Form: 6-K · Filed: Sep 4, 2024 · CIK: 1625297

Sentiment: neutral

Topics: drug-development, pipeline-update, pharmaceutical

TL;DR

Indivior PLC is moving forward with AEF0117, a new drug candidate.

AI Summary

Indivior PLC announced an update on its investigational drug AEF0117 on September 4, 2024. The company is progressing with the development of this novel treatment.

Why It Matters

This update signals continued progress in Indivior's drug development pipeline, potentially impacting future revenue streams and treatment options for patients.

Risk Assessment

Risk Level: low — The filing is a routine update on drug development progress without significant financial or operational changes.

Key Players & Entities

FAQ

What is AEF0117?

AEF0117 is an investigational drug being developed by Indivior PLC.

When was the update provided?

The update was provided on September 4, 2024.

Where is Indivior PLC based?

Indivior PLC's principal executive office is located at 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Virginia 23235.

What form is this filing?

This filing is a Form 6-K, a Report of Foreign Private Issuer.

What is the SIC code for Indivior PLC?

The Standard Industrial Classification code for Indivior PLC is 2834, Pharmaceutical Preparations.

Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-09-04 08:28:07

Filing Documents

SIGNATURES

SIGNATURES         Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Indivior PLC   Date: September 04, 2024 /s/ Kathryn Hudson   Name: Kathryn Hudson   Title: Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing